AstraZeneca announced positive Phase 3 trial results for gefurulimab, a once-weekly, self-administered C5 complement inhibitor for adults with generalized myasthenia gravis who have anti-acetylcholine receptor antibodies. The PREVAIL trial met its primary and all secondary endpoints, showing statistically and clinically meaningful improvements in daily living activities scores. This paves the way for regulatory discussions and potential commercialization for this rare autoimmune disorder, enhancing AstraZeneca’s presence in neurology therapeutics.